Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.64 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | HCK | P08631 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 4/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.49 |
| ▸ | PRKDC | P78527 | 4/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718270 | 1.00 | PIK3CD (0.64) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL13828398 | 1.00 | PIK3CD (0.64) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL131081 | 0.93 | PIK3CD (0.72) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL15582861 | 0.93 | PIK3CD (0.72) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL29651637 | 0.93 | PIK3CD (0.72) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL10790 | 0.93 | PIK3CD (0.72) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL29651776 | 0.93 | PIK3CD (0.71) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL11793 | 0.93 | PIK3CD (0.71) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL13717811 | 0.93 | PIK3CD (0.56) | PIK3CDPIK3CGCSNK1EPIK3R1SRC | |
| SCHEMBL13717658 | 0.93 | PIK3CD (0.63) | PIK3CDPIK3CGCSNK1EPIK3R1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CG 77/4885CSNK1E 110/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | PIK3CD 288/4885PIK3CG 406/4885CSNK1E 122/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CG 77/4885CSNK1E 110/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CG 77/4885CSNK1E 110/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | PIK3CD 89/4885PIK3CG 128/4885CSNK1E 24/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | PIK3CD 30/4885PIK3CG 60/4885CSNK1E 119/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CG 77/4885CSNK1E 110/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CG 77/4885CSNK1E 110/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | PIK3CD 148/4885PIK3CG 194/4885CSNK1E 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.